Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO E-Learning: Practical Management of Patients with Advanced NSCLC: Cisplatin or Carboplatin Combination Therapies

Learning objectives

  • To discuss issues which challenge the equivalence of two platinum compounds (cis- and carboplatin) in the treatment of patients with advanced non-small cell lung cancer (NSCLC)
  • To understand the pharmacology of platinum compounds and how it impacts on the management issues in solid tumours and especially NSCLC
  • To provide clinical practice recommendations for the selection of platinum compound based on expected toxicity profile, patient organ function, patient comorbidities, and companion drug(s)

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.

Title Duration Content CME Points CME Test
Practical Management of Patients in Advanced NSCLC: Cisplatin or Carboplatin Combination Therapies 25 min. 41 slides - -

This E-Learning module discusses an old issue in oncology, whether two platinum compounds (cis- and carboplatin) are equal in the management of patients with advanced non-small cell lung cancer (NSCLC). The question has an important practical aspect, considering an easier carboplatin administration in the daily practice, with no need for pre/post hydration as in case of cisplatin. Introduced in the clinic with similar mechanism of action, but with significantly different toxicity profile, it is unclear whether their clinical efficacy is the same.

The authors discuss this endless issue by covering renewed rivalry from the aspects of pharmacology of platinum compounds, mechanism of action, toxicity profile, and extensively management issues such as platinum compounds vs. best supportive care, platinum compounds vs. single agent therapy, platinum compounds vs. non-platinum based treatment, and thereafter a direct comparison of cis- vs. carboplatin-based chemotherapy, providing very practical conclusions based on findings from randomised clinical trials and meta-analysis.

By discussing findings from the direct comparison of therapies based on these two platinum agents, this E-Learning module provides very practical considerations about which of these two performs better in terms of activity, treatment efficacy, and also in terms of toxicity.

In conclusion, the authors underline that selection of the platinum compound in the first-line treatment of patients with advanced NSCLC should take into account the expected toxicity profile, the patient organ function, the comorbidities, and the companion drug(s). This is a very practice-oriented, educational material, particularly suitable when faced with a simple, but important clinical practice dilemma.

This E-Learning module was published in 2012 and expired in 2015.

Last update: 20 Dec 2012

Dr Garassino has reported to be a consultant for Ely Lilly and Boehringer Ingelheim and a member of the speakers' bureau for Ely Lilly. Dr Rossi has reported no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings